LUMATEPERONE (ITI-007) FOR THE TREATMENT OF SCHIZOPHRENIA: PLACEBO-CONTROLLED CLINICAL TRIALS AND AN OPEN-LABEL SAFETY SWITCHING STUDY

被引：17
|
作者：
Vanover, Kimberly [1 ]
Dmitrienko, Alex [2 ]
Glass, Steven [1 ]
Kozauer, Susan [1 ]
Saillard, Jelena [1 ]
Weingart, Michal [1 ]
Satlin, Andrew [1 ]
Mates, Sharon [1 ]
Correll, Christoph [3 ]
Davis, Robert [1 ]
机构：
[1] Intra Cellular Therapies Inc, New York, NY USA
[2] Mediana Res, Ljubljana, Slovenia
[3] Hofstra North Shore LIJ Sch Med, Zucker Hillside Hosp, Hempstead, NY USA
来源：
SCHIZOPHRENIA BULLETIN | 2018年 / 44卷
关键词：
D O I：
10.1093/schbul/sby018.831
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
S44
引用
收藏
页码：S341 / S341
页数：1
相关论文
共 50 条
  • [41] Comparison of placebo-controlled and open label trials in pulmonary arterial hypertension
    Moeller, A
    Given, M
    Coyne, T
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 275 - 275
  • [42] A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises
    Pae, Chi-Un
    Seo, Ho-Jun
    Lee, Boung Chul
    Seok, Jeong-Ho
    Jeon, Hong Jin
    Paik, Jong-Woo
    Kwak, Kyung-Phil
    Ham, Byung-Joo
    Han, Changsu
    Lee, Soo-Jung
    [J]. PSYCHIATRY INVESTIGATION, 2014, 11 (04) : 371 - 379
  • [43] Comparison of placebo-controlled and open label trials in pulmonary arterial hypertension
    Allison, A.
    Given, M.
    Coyne, T. C.
    [J]. EUROPEAN HEART JOURNAL, 2005, 26 : 81 - 81
  • [44] Attitudes of patients with schizophrenia toward placebo-controlled clinical trials
    Hummer, M
    Holzmeister, R
    Kemmler, G
    Eder, U
    Hofer, A
    Kurzthaler, I
    Oehl, M
    Weiss, E
    Fleischhacker, WW
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (03) : 277 - 281
  • [45] Placebo-controlled clinical trials of new atypical antipsychotics in schizophrenia
    Czobor, P.
    Komlosi, S.
    Bitter, I.
    [J]. EUROPEAN PSYCHIATRY, 2008, 23 : S157 - S157
  • [46] ITI-007, A FIRST-IN-CLASS INVESTIGATIONAL NEW DRUG FOR THE TREATMENT OF SCHIZOPHRENIA: PHASE 2 CLINICAL TRIAL EFFICACY AND SECONDARY ANALYSES
    Vanover, Kimberly
    Mates, Sharon
    Davis, Robert
    [J]. SCHIZOPHRENIA BULLETIN, 2015, 41 : S337 - S337
  • [47] NOVEL USE OF PRECLINICAL AND CLINICAL DATA TO PREDICT THERAPEUTIC DOSE RANGES FOR ITI-007, A POTENTIAL TREATMENT FOR SCHIZOPHRENIA AND OTHER NEUROPSYCHIATRIC DISORDERS
    Vanover, Kimberly
    Fienberg, A. A.
    Wennogle, L. P.
    Mates, S.
    Davis, R. E.
    [J]. SCHIZOPHRENIA BULLETIN, 2009, 35 : 340 - 341
  • [48] Safety and efficacy of paliperidone extendedrelease in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
    Zhang, Hongyan
    Li, Huafang
    Liu, Yanning
    Wu, Cathy
    Wu, Qingqi
    Nuamah, Isaac
    Shi, Jianguo
    Xie, Shiping
    Wang, Gang
    Gopal, Srihari
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 69 - 77
  • [49] Topiramate in migraine prophylaxis: An open-label extension of a double-blind, placebo-controlled study
    Hart, DE
    Calder, CS
    Storey, JR
    Riback, P
    Potter, DL
    Wymer, JP
    Beesley, BA
    [J]. NEUROLOGY, 2002, 58 (07) : A496 - A497
  • [50] Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia
    Storosum, JG
    van Zwieten, BJ
    Wohlfarth, T
    de Haan, L
    Khan, A
    van den Brink, W
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (04) : 365 - 368
12345